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Toxicity is an inevitable consequence of cancer treatment.   
While patients want curative treatment if possible, quality of 
life issues have been somewhat neglected in the race to 
improve survival.   Patient reported outcome measures 
(PROMS) confirm that most routinely used clinical scoring 
systems fail to identify important toxicities and as a result 
the frequency, severity and impact on patients’ lives of 
chronic GI consequences of cancer therapies has historically 
not been fully recognised by clinicians.   Nor has it received 
the attention that it deserves in terms of research.  Yet the 
iatrogenically driven morbidity of cancer treatments and 
especially radiotherapy is an important human model of GI 
disease and has already yielded new insights which can be 
applied to benign and malignant diseases. 
In the last 20 years, a largely unheralded but spectacular 
revolution in understanding why toxicity develops, how it 
should be identified, measured and managed has gathered 
speed.   Inaccurate terminology describing toxicity in the 
past has significantly hindered progress.  It is now recognised 
that toxicities rarely affect just one organ system and the 
concept that toxicities after radical treatment are a 
progressive disease, Pelvic Radiation Disease, have helped 
formulate more productive treatment approaches and 
understand future priorities.  Clinical studies now show that 
applying this new understanding allows much GI toxicity 
previously widely regarded as incurable to be ameliorated.  
In addition, biomarkers of radiation toxicity – fibrotic markers 
which can be measured in blood are the most promising – 
offer a much more accurate method of detecting toxicity 
than the current approach of defining toxicity by a change in 
symptoms and this is starting to allow new methods of 
preventing toxicity, to be targeted more accurately.   
It is also increasingly understood that the “consequential 
effect” has a critical role in the development of chronic 
toxicity and that it is driven by factors beyond the control of 
the oncologist. One of the most important of these is the 
composition of the gut microbiota; another is the role of the 
immune system.  Introducing techniques already used by 
other disciplines to manipulate these factors will deliver 
future great rewards in terms of reducing chronic toxicity. 
GI toxicity is a major limiting factor to the advance of 
oncological treatments.  Many new solutions have emerged 
but require the harnessing of a multidisciplinary approach in 
a way that oncology has rarely used up to this point.   
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Intestinal radiation injury may severely hamper quality of life 
during and after treatment of abdominal tumors. Even though 
novel technical advances in treatment delivery have enabled 
more selective irradiation of the tumor, normal tissue 
radiation injury remains the most important dose limiting 
factor of radiotherapy. Hence, there is an urgent need for 
agents that can be administered during radiotherapy to 
prevent and/or reduce radiation-induced intestinal injury. 
These agents should of course not hamper the anti-tumor 
effect of radiation and, ideally, even improve radiation-
induced tumor cell kill.  
Pre-clinical studies have shown that the novel Somatostatin 
analogue Pasireotide effectively reduces radiation-induced 
intestinal injury by preventing post-irradiation pancreatic 
enzyme-dependent intestinal auto-digestion. In our 
experiments Pasireotide was shown to preserve the intestinal 
mucosal surface and to prevent intestinal bacterial 
translocation after radiation exposure. Pasireotide did not 
protect the intestinal stem cells and the beneficial effect of 
Pasireotide could be reversed by pancreatic enzyme 
substitution.  Therefore, Pasireotide does not seem to act as 
a cytoprotector, but to mitigate intestinal radiation injury by 
inhibiting pancreatic exocrine secretion.  
Until recent, knowledge on the effects of Pasireotide on the 
radiation-induced tumor response was scarce or non-existing 
at all. Pre-clinical studies have shown that Pasireotide may 
have a direct inhibiting effect on the growth of certain 
tumors such as neuroendocrine cancers. Moreover, it may 
reduce tumor growth by reducing the availability of growth 
factors such as IGF-1 and VEGF. However, no studies have 
been performed to assess the effect of Pasireotide on 
radiation-induced tumor growth delay. As Pasireotide can 
only be considered for clinical use if it does not hamper the 
anti-tumor effect of radiotherapy, we tested the effect of 
Pasireotide on tumor response to radiation in an animal 
model. The results of this recently performed study may 
enable a trial to test the potential beneficial effect on 
intestinal radiation injury in patients.  
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The increasing number of dose escalation and 
hypofractionation prostate cancer trials is providing us 
excellent opportunities to learn more about ano-rectal, 
